To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy

NCT00325117 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
200
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis